BiotechTubeBiotechTube
Home/Taysha Gene Therapies/Frederick Porter, Ph.D.
FP

Frederick Porter, Ph.D.

Chief Technical Officer

Taysha Gene Therapies

Therapeutic Areas

NeurologyRare DiseasesGenetic Disorders

Taysha Gene Therapies Pipeline

DrugIndicationPhase
TSHA-102Rett SyndromePhase 1/2
TSHA-120Giant Axonal Neuropathy (GAN)Phase 1/2
TSHA-101GM2 Gangliosidosis (Tay-Sachs/Sandhoff)Preclinical
TSHA-103SLC6A1-related disorderPreclinical
TSHA-104SURF1-associated Leigh syndromePreclinical
TSHA-105FOXG1 syndromePreclinical
TSHA-106SCN8A-related disorderPreclinical
TSHA-107SYNGAP1-related disorderPreclinical

Leadership Team at Taysha Gene Therapies

SP
Sean P. Nolan
Executive Chairman of the Board
KA
Kamran Alam
Chief Financial Officer
SN
Sukumar Nagendran, M.D.
President, Chief Medical Officer, and Interim Chief Executive Officer
RS
R.A. Session, M.S., M.B.A.
Founder, Former President and Chief Executive Officer
BZ
Brett Zankel, Ph.D.
Senior Vice President, Business Development
SR
Steven R. Deitcher, M.D.
Former Director
PB
Phillip B. Donenberg
Director
JB
James B. Posey
Director
RB
Richard Barry
Director
RP
Rajiv Patni, M.D.
Director
View full Taysha Gene Therapies profile